Gurpreet Jutley1, Karim Raza, Christopher D Buckley. 1. Rheumatology Research Group, Centre for Translational Inflammation Research, University of Birmingham, Edgbaston, Birmingham, UK.
Abstract
PURPOSE OF REVIEW: Rheumatoid arthritis (RA) is a heterogeneous chronic immune-mediated inflammatory disease, associated with significant morbidity and reduced life expectancy. Here, we review recent discoveries; particularly those which have attempted to integrate genome-wide association studies (GWAS) with biological pathways and cell types known to play a role in disease pathology in order to expand our current understanding of the pathogenesis of RA. As the role of stromal cells in the pathogenesis of RA has been reviewed in detail in Current Opinions in Rheumatology, this area will not be covered in this review. RECENT FINDINGS: Although our understandings of the pathogenic processes that drive disease in RA remain incomplete, remarkable advances over the past year can be highlighted. GWAS have raised awareness of important new risk loci with genes that either are the targets of approved therapies for RA, or involve pathways for drugs that could be repurposed from other disease indications such as cancer. Furthermore, promising strides have been made in predicting the likelihood of developing RA in those at risk using human leukocyte antigen (HLA), smoking, and autoantibody status prediction models. These findings give a fresh insight into RA pathogenesis and help identify new, or repurpose known therapeutic targets from other disease areas. SUMMARY: The findings discussed in this review underscore the progress made to date and the need for future studies, investigating disease mechanisms in RA, with particular interest in at-risk RA gene loci, their function in immune and stromal cells within the synovium, and how they interact with environmental factors to initiate and perpetuate disease.
PURPOSE OF REVIEW: Rheumatoid arthritis (RA) is a heterogeneous chronic immune-mediated inflammatory disease, associated with significant morbidity and reduced life expectancy. Here, we review recent discoveries; particularly those which have attempted to integrate genome-wide association studies (GWAS) with biological pathways and cell types known to play a role in disease pathology in order to expand our current understanding of the pathogenesis of RA. As the role of stromal cells in the pathogenesis of RA has been reviewed in detail in Current Opinions in Rheumatology, this area will not be covered in this review. RECENT FINDINGS: Although our understandings of the pathogenic processes that drive disease in RA remain incomplete, remarkable advances over the past year can be highlighted. GWAS have raised awareness of important new risk loci with genes that either are the targets of approved therapies for RA, or involve pathways for drugs that could be repurposed from other disease indications such as cancer. Furthermore, promising strides have been made in predicting the likelihood of developing RA in those at risk using human leukocyte antigen (HLA), smoking, and autoantibody status prediction models. These findings give a fresh insight into RA pathogenesis and help identify new, or repurpose known therapeutic targets from other disease areas. SUMMARY: The findings discussed in this review underscore the progress made to date and the need for future studies, investigating disease mechanisms in RA, with particular interest in at-risk RA gene loci, their function in immune and stromal cells within the synovium, and how they interact with environmental factors to initiate and perpetuate disease.
Authors: Sonia Unriza-Puin; Wilson Bautista-Molano; Gloria I Lafaurie; Rafael Valle-Oñate; Philippe Chalem; Lorena Chila-Moreno; Juan Manuel Bello-Gualtero; Consuelo Romero-Sánchez Journal: Clin Rheumatol Date: 2016-12-28 Impact factor: 2.980
Authors: Mario Mellado; Laura Martínez-Muñoz; Graciela Cascio; Pilar Lucas; José L Pablos; José Miguel Rodríguez-Frade Journal: Front Immunol Date: 2015-07-27 Impact factor: 7.561
Authors: Junzeng Fu; Bart V J Cuppen; Paco M J Welsing; Herman van Wietmarschen; Amy C Harms; Ruud Berger; Slavik Koval; Ruth D E Fritsch-Stork; Johannes W J Bijlsma; Thomas Hankemeier; Jan van der Greef; Floris P J G Lafeber Journal: Inflammopharmacology Date: 2016-09-28 Impact factor: 4.473